At a glance: Two S&P 500 names sit on today's roster — Kroger, time unconfirmed, and Cooper Companies after the close — before Thursday hands the week its main event in Oracle. Casey's is graded below, and it carries the morning's real lesson: an 8.1% EPS beat that the tape answered with an 11.9% drop.

The tape ahead

Kroger heads the roster with its reporting time still unconfirmed, and that deserves a flag: the company's own investor calendar points to Friday morning rather than today, so the print may not land until the end of the week. The set-up is the same whenever it does. Consensus of $1.05 in EPS (down 33.2% vs prev.Q.) on $34.56B of revenue (down 25.1% vs prev.Q.) looks like a collapse and is nothing of the sort: Kroger's fiscal first quarter runs sixteen weeks against twelve for the second, so a quarter of the sequential base disappears on the calendar alone — the revenue step-down is almost exactly that arithmetic, with EPS falling further on the operating leverage those four extra weeks carry. The comparison that matters is the $1.04 earned in the year-ago quarter, against which consensus is essentially flat. The debate is identical sales: the first quarter landed at the very bottom of the annual range, and the question is whether the grocer can hold that floor without buying traffic through price, while lower Medicare drug reimbursement keeps working through a pharmacy business that flatters the sales line and dilutes the margin line at the same time. The offsets — digital volume and the retail-media arm, both compounding at rates the core cannot match — are what the multiple is actually paying for, and the capital-allocation question sits alongside them, with a residual buyback authorization now competing against the Giant Eagle acquisition and a heavy capital-spending year. Options price a 5.5% move into Friday's expiry against a 4.9% average realized move over the last eight prints — the most evenly priced straddle on this week's board, and with an 88% beat rate the signal is that the EPS line is rarely the event here. Trailing EPS growth reads brutally (-58.1% 1-year, -20.5% 3-year, -14.1% 5-year, -2.9% 10-year), but that is an as-reported annual series dominated by the impairment Kroger booked against its e-commerce fulfillment network, not a description of the earnings power the guide is built on.

Cooper Companies follows after the close, with consensus at $1.12 in EPS (down 7.4% vs prev.Q.) on $1.10B of revenue (up 1.5% vs prev.Q.) — earnings expected to give back ground while the top line inches ahead, which is a margin-and-mix statement rather than a demand one. Against the $1.10 booked a year ago the quarter is flat, and none of that is why this name carries an 8.3% straddle. The strategic review the board opened in December, with a sale of CooperSurgical the question on the table, has run long enough that an answer — or another delay — will move the stock further than any plausible miss on the quarter; the fertility-media litigation that hung over that process has since been settled, removing the most obvious reason to keep waiting. Underneath it, CooperVision's growth has been carried by the premium end — torics, multifocals and the MyDay franchise — with Asia-Pacific the soft spot, and PARAGARD now faces its first credible non-hormonal rival in four decades, a flexible copper device licensed for a US launch late this year that speaks directly to CooperSurgical's terminal value. Set against all of that, an 8.3% implied move versus a 1.3% average realized move over the last eight prints is the widest implied-to-realized gap on today's board, and it sits on a name that has beaten in every one of those eight quarters: the options market is not pricing the print, it is pricing the review and the guide. The trailing record explains the tension — -4.2% over one year and -1.1% over three against +9.3% and +6.1% over five and ten, a compounder whose compounding stopped.

Scorecard — reported since we last wrote

Casey's delivered the beat and got none of the credit. EPS of $7.37 came in 8.1% ahead of the consensus we flagged, revenue beat by 2.2%, and reported EPS was up 68.6% on the prior quarter — the summer seasonal peak doing its work — and the stock still fell 11.9% after the close, a move larger than the one options had priced for the event and pointed against both surprises. The two lines agreed, so this is not a case of EPS and revenue telling different stories; it is a stock re-rated on a freshly announced store-expansion plan being marked on the outlook rather than on the quarter. That is the useful read into tonight: where a name carries a plan-driven multiple, the guide is the print.

Rest of the week

Thursday is the week. Oracle, Adobe and Copart all report after the close, and Oracle's 11.7% implied move is the largest single-name event on the calendar — an AI-infrastructure print that the whole capital-spending complex will trade off. Adobe follows at 8.3%, where the argument is whether generative tooling is converting into paid seats quickly enough to matter to a business this size. No implied move is quoted for Copart, the quietest of the three and the cleanest read available on US insurance claim volumes.

Informational only — not investment advice. Figures are consensus/estimates and option-implied values from public sources and may be revised.